901P - Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045
| Autor: | Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D., Choueiri, T.K., Necchi, A., Gerritsen, W.R., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Jensen, E., Frenkl, T., Perini, R.F., Bajorin, D. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|